FDA rejects Replimune’s oncolytic virus
There are questions about vuso-vec’s supporting and confirmatory trials.
Replimune challenges Iovance
The company’s vuso-vec looks similar to Amtagvi, and could have safety and convenience advantages.
ASCO 2024 abstract movers – Merus convinces, at first
Thursday's unveiling of regular ASCO abstract yielded a few initial winners and losers.
FDA green and red lights: Q1 2024
A roundup of the first quarter's key oncology drug approvals and rejections.
The new normal in US oncology approvals
Nearly two thirds of key oncology filings are expedited; and what about the ones that aren’t?
Will the tills ring for Iovance?
The group has approval for Amtagvi, but now faces the prospect of a solo launch.
Make or break time for Iovance
Lifileucel heads up the list of upcoming US FDA catalysts.
Christmas holiday round-up
As the biotech markets turned bullish the sector’s ups and downs continued.
